INCYTE CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
INCYTE CORPORATION (INCY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $41.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-10
- INCYTE CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $41.80M, a 1206.25% increase from fiscal 2024.
- INCYTE CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.20M, a 0.00% change from fiscal 2023.
- INCYTE CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $3.20M, a 46.67% decline from fiscal 2022.
- INCYTE CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $6.00M, a 52.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $41.80M 10-K · filed 2026-02-10 |
| 2024-12-31 | $3.20M 10-K · filed 2026-02-10 |
| 2023-12-31 | $3.20M 10-K · filed 2026-02-10 |
| 2022-12-31 | $6.00M 10-K · filed 2025-02-10 |
| 2021-12-31 | $12.70M 10-K · filed 2024-02-13 |
| 2020-12-31 | $87.50M 10-K · filed 2023-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |